問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Division of General Surgery

Division of Urology

更新時間：2023-09-19

郭永嘉Kao, Yung-Chia
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

Recruiting Trial

79Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

郭永嘉

List

128Cases

2015-07-01 - 2019-03-31

Phase I

A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients with Advanced Solid Tumours

  • Condition/Disease

    Advanced Solid Tumours

  • Test Drug

    MEDI4736

Participate Sites
3Sites

Not yet recruiting3Sites

陳仁熙
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2014-06-01 - 2017-12-31

Phase III

A randomized, double-blinded, placebo controlled, multicentre phase III study to assess the efficacy and safety of olaparib (AZD2281) in combination with paclitaxel, compared to placebo in combination with paclitaxel, in Asian patients with advanced gastric cancer (including the gastro-oesophageal junction) who have progressed following first line therapy

  • Condition/Disease

    advanced gastric cancer

  • Test Drug

    Olaparib

Participate Sites
5Sites

Terminated5Sites

2020-08-01 - 2025-07-01

Phase I

A Phase 1, Multi-center, Open Label First-in-Human Study With ABBV-CLS-579 Alone and in Combination With Anti-PD-1 in Subjects With Locally Advanced or Metastatic Tumors

  • Condition/Disease

    Locally Advanced or Metastatic Tumors

  • Test Drug

    ABBV-CLS-579

Participate Sites
4Sites

Not yet recruiting1Sites

Recruiting3Sites

2023-12-01 - 2027-03-31

Phase II

A Phase 2, Randomized Study to Evaluate Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination With Fluorouracil, Folinic Acid, and Bevacizumab in Previously Treated Subjects With Unresectable Metastatic Colorectal Cancer

  • Condition/Disease

    Unresectable Metastatic Colorectal Cancer

  • Test Drug

    ABBV-400

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting3Sites

2019-10-01 - 2023-01-13

Phase II

A phase 2, multicenter open-label, non-randomized study of bavituximab plus pembrolizumab in patients with advanced gastric or gastroesophageal cancer who have progressed on or after at least one prior standard therapy

  • Condition/Disease

    Gastric Cancer / GastroEsophageal Cancer

  • Test Drug

    Bavituximab

Participate Sites
4Sites

Recruiting4Sites

2021-04-01 - 2024-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2017-01-06 - 2022-01-05

Phase III

ONO-4538 Phase III Study A multicenter, double-blind, randomized study in patients with gastric cancer undergoing postoperative adjuvant chemotherapy

  • Condition/Disease

    Gastric Cancer

  • Test Drug

    Nivolumab

Participate Sites
10Sites

Terminated8Sites

白禮源
China Medical University Hospital-Taipei

未分科

陳仁熙
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2016-07-28 - 2020-11-01

Phase III

A Phase 3, Multicenter, Multinational, Randomized, Open-Label, Parallel-Arm Study of Avelumab (MSB0010718C) Plus Best Supportive Care Versus Best Supportive Care Alone as a Maintenance Treatment in Patients with Locally Advanced or Metastatic Urothelial Cancer Whose Disease Did Not Progress After Completion of First-Line Platinum-Containing Chemotherapy

  • Condition/Disease

    Locally Advanced or Metastatic Urothelial Cancer

  • Test Drug

    Avelumab (MSB0010718C)

Participate Sites
6Sites

Terminated6Sites

2016-07-05 - 2020-07-05

Phase II

ONO-4538 Phase II/III Study Multicenter, Open-Label, Randomized Study in Patients with Unresectable Advanced or Recurrent Gastric Cancer

  • Condition/Disease

    Advanced or Recurrent Gastric Cancer

  • Test Drug

    Nivolumab

Participate Sites
12Sites

Terminated10Sites

陳仁熙
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

白禮源
China Medical University Hospital-Taipei

未分科

2014-11-01 - 2022-02-28

Phase III

A Phase 3, Multicenter, Open-label, Randomized Study of nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma

  • Condition/Disease

    Pancreatic Adenocarcinoma

  • Test Drug

    nab-Paclitaxel

Participate Sites
6Sites

Terminated6Sites

1 8 9 10 11 12 13
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB